| | Title | Author(s) | Year | View Count | | 1 |  | Two-stage dose finding for cytostatic agents in phase I oncology trials | Yin, G; Zheng, S; Xu, J | 2013 | 51 |
| 2 | | Phase II trial design with Bayesian adaptive randomization and predictive probability | Yin, G; Chen, N; Jack Lee, J | 2012 | 97 |
| 3 | | A general transformation class of semiparametric cure rate frailty models | Diao, G; Yin, G | 2012 | 91 |
| 4 | | Worth adapting? Revisiting the usefulness of outcome-adaptive randomization | Lee, JJ; Chen, N; Yin, G | 2012 | 49 |
| 5 |  | Two-stage dose finding for cytostatic agents in phase I oncology trials | Yin, G; Zheng, S; Xu, J | 2012 | 42 |
| 6 |  | Bayesian Dose Finding for Combined Drugs with Discrete and Continuous Doses | Huo, L; Yuan, Y; Yin, G | 2012 | 68 |
| 7 | | Bayesian phase II adaptive randomization by jointly modeling time-to-event efficacy and binary toxicity | Lei, X; Yuan, Y; Yin, G | 2011 | 256 |
| 8 | | Efficiency improvement in a class of survival models through model-free covariate incorporation | Garcia, TP; Ma, Y; Yin, G | 2011 | 85 |
| 9 | | Dose-response curve estimation: A semiparametric mixture approach | Yuan, Y; Yin, G | 2011 | 105 |
| 10 | | On the usefulness of outcome-adaptive randomization | Yuan, Y; Yin, G | 2011 | 74 |
| 11 | | Stochastic generalized method of moments | Yin, G; Ma, Y; Liang, F; Yuan, Y | 2011 | 174 |
| 12 | | Bayesian phase I/II adaptively randomized oncology trials with combined drugs | Yuan, Y; Yin, G | 2011 | 87 |
| 13 | | Bayesian hybrid dose-finding design in phase I oncology clinical trials | Yuan, Y; Yin, G | 2011 | 108 |
| 14 | | Censored quantile regression with covariate measurement errors | Ma, Y; Yin, G | 2011 | 186 |
| 15 | | Robust EM continual reassessment method in oncology dose finding | Yuan, Y; Yin, G | 2011 | 96 |
| 16 | | Methylation of the candidate biomarker TCF21 is very frequent across a spectrum of early-stage nonsmall cell lung cancers | Richards, KL; Zhang, B; Sun, M; Dong, W; Churchill, J; Bachinski, LL; Wilson, CD; Baggerly, KA; Yin, G; Hayes, DN; Wistuba, II; Krahe, R | 2011 | 113 |
| 17 | | Phase III randomized trial of dose intensive neoadjuvant chemotherapy with or without G-CSF in locally advanced breast cancer: Long-term results | Arun, BK; Dhinghra, K; Valero, V; Kau, SW; Broglio, K; Booser, D; Guerra, L; Yin, G; Walters, R; Sahin, A; Ibrahim, N; Buzdar, AU; Frye, D; Sneige, N; Strom, E; Ross, M; Theriault, RL; VadhanRaj, S; Hortobagyi, GN | 2011 | 78 |
| 18 | | Sex determining region Y-box 2 (SOX2) is a potential cell-lineage gene highly expressed in the pathogenesis of squamous cell carcinomas of the lung | Yuan, P; Kadara, H; Behrens, C; Tang, X; Woods, D; Solis, LM; Huang, J; Spinola, M; Dong, W; Yin, G; Fujimoto, J; Kim, E; Xie, Y; Girard, L; Moran, C; Hong, WK; Minna, JD; Wistuba, II | 2010 | 117 |
| 19 | | Bayesian quantile regression for longitudinal studies with nonignorable missing data | Yuan, Y; Yin, G | 2010 | 150 |
| 20 | | Semiparametric median residual life model and inference | Ma, Y; Yin, G | 2010 | 278 |
|
